Oncology CDMO Market 2026-2034 | Growth, Opportunities & Forecast
Coverage: Oncology CDMO Market covers analysis By Service Type (Drug Product Manufacturing, Cell & Gene Therapy CDMO Services); Drug Type (Monoclonal Antibodies, Antibody-Drug Conjugates (ADCs)); Phase (Clinical (Phase I, II, III), Commercial); End-User (Large Pharmaceutical Companies, Biotechnology Companies); and Geography
- Report Date : Feb 2026
- Report Code : TIPRE00042203
- Category : Life Sciences
- Status : Upcoming
- Available Report Formats :
- No. of Pages : 150
The oncology CDMO market size is projected to reach USD 115.22 billion by 2034, up from USD 48.52 billion in 2025, growing at a CAGR of 10.09% during the forecast period 2026–2034.
Oncology CDMO Market AnalysisThe oncology CDMO market is expanding rapidly due to rising cancer prevalence, growing demand for advanced therapies such as antibody-drug conjugates (ADCs), cell and gene therapies, and the integration of AI-driven efficiencies. CDMOs are increasingly relied upon for scalable solutions across preclinical development, clinical trial material production, and commercial manufacturing. The market is also driven by the need for regulatory compliance, cost-effective infrastructure, and accelerated time-to-market for oncology drugs.
Oncology CDMO Market OverviewOncology CDMOs (Contract Development and Manufacturing Organizations) provide outsourcing services for the development, manufacturing, and packaging of oncology drugs. These services span preclinical development, formulation, analytical testing, regulatory support, and commercial-scale production. The complexity of cancer drugs, including biologics, ADCs, and highly potent APIs (HPAPIs), necessitates specialized CDMO capabilities. CDMOs enable pharmaceutical and biotech companies to reduce infrastructure costs, ensure compliance, and accelerate drug development timelines.
Strategic Insights
Oncology CDMO Market Drivers and OpportunitiesMarket Drivers:
- Rising Global Cancer Burden and Demand for Innovative Therapies: The global increase in cancer cases creates massive demand, which complicates treatment, and clinical trial complexity is a major driver. While dealing with this challenge, the demand for CDMO services has increased to accelerate the development and manufacturing of next-generation oncology drugs.
- Increasing Adoption of Biologics, ADCs, and Cell & Gene Therapies: The global shift towards sophisticated large-molecule therapies has greatly enhanced the scope of the CDMO market. Technology in cancer treatment is shifting from chemotherapy to highly specific treatments, and specialized CDMO capabilities are advancing to underpin this transformation further.
- Favorable Regulatory Pathways: Oncology CDMO services are among a variety of outsourcing solutions whose widespread implementation is actively supported by governments worldwide. Starting from the new health tech programs, such as accelerated approvals and fast-track designations, pharmaceutical clients are being incentivized to move away from slow internal capacity build-up and adopt accelerated time-to-market paths.
Market Opportunities:
- Expansion in Emerging Markets: Emerging markets such as the Asia-Pacific are witnessing an increased adoption of CDMO services due to the expansion of clinical trials and the development of cost-effective manufacturing hubs. Cost-efficient offerings provide scalable, effective solutions to meet growing demand in these regions.
- Growth in Personalized Medicine and Small-Batch Manufacturing: Integration of advanced manufacturing technologies will provide seamless production management for highly specific and customized therapies. Small-batch and localized manufacturing allows customization of therapy, reduces waste, and sets the efficient utilization of resources.
- Strategic Partnerships and M&A to Expand Global CDMO Capabilities: The trend for specialization in oncology manufacturing is the main driver of strategic M&A. Strategic acquisitions and facility expansions signal growing investor confidence in the CDMO model. Such moves enable innovation consolidation, cut down the R&D burden, and set the efficient utilization of resources, thus contributing to the improvement of global supply chain stability.
The oncology CDMO market share is analyzed across various segments to provide a clearer understanding of its structure, growth potential, and emerging trends. Below is the standard segmentation approach used in most industry reports:
By Service Type:
- Drug Product Manufacturing: Integrated services covering final formulation, fill/finish, and packaging.
- Cell & Gene Therapy CDMO Services: Specialized manufacturing for viral vectors and cell manipulation.
By Drug Type:
- Monoclonal Antibodies: Large-volume production of therapeutic antibodies.
- Antibody-Drug Conjugates (ADCs): Highly complex and specialized manufacturing of linked biologics and cytotoxic drugs.
By Phase:
- Clinical (Phase I, II, III): Manufacturing services for clinical trial material.
- Commercial: Large-scale, high-volume production for market supply.
By End-User:
- Large Pharmaceutical Companies: Outsourcing to optimize costs and focus on core R&D.
- Biotechnology Companies: Rely on CDMOs for scale-up, regulatory expertise, and facility access.
By Geography:
- North America
- Europe
- Asia Pacific
- South & Central America
- Middle East & Africa
The oncology CDMO market in the Asia Pacific is expected to witness the fastest growth during the forecast period, driven by rising cancer incidence and the availability of cost-efficient manufacturing in the region.
Market Report Scope
Oncology CDMO Market Share Analysis by GeographyThe Asia Pacific region is expected to show the highest growth rate in the coming years, primarily driven by favourable manufacturing costs and expanding healthcare access. Emerging markets in South & Central America, the Middle East, and Africa also present significant opportunities for CDMO providers. The oncology CDMO market shows a different growth trajectory in each region due to factors such as healthcare infrastructure, regulatory environment, and advanced technology adoption. Below is a summary of market share and trends by region:
North America
- Market Share: Dominant due to advanced healthcare infrastructure, high research investment, and a strong R&D ecosystem.
- Key Drivers: High concentration of clinical trials, robust FDA support, and heavy investment in bioconjugates and biologics.
- Trends: Increasing demand for specialized fill/finish capacity and rapid adoption of advanced modalities like Cell & Gene Therapy and Antibody-Drug Conjugate (ADC) manufacturing.
Europe
- Market Share: Significant due to stringent regulatory standards (EMA) and consistent public funding for medical research.
- Key Drivers: National reimbursement programs and innovation in key pharmaceutical hubs like Germany, Switzerland, and France.
- Trends: Market consolidation driven by larger players acquiring specialized smaller CDMOs, alongside a strong focus on sustainable and green API manufacturing practices.
Asia Pacific
- Market Share: Fastest-growing region, owing to cost-efficient manufacturing and rapid healthcare digitalization.
- Key Drivers: Rising cancer prevalence, government support for the pharmaceutical industry, and expanding opportunities for cost-efficient production.
- Trends: Significant capacity expansion for biosimilar and small-molecule production, coupled with investment in modernizing facilities to meet global GMP export standards.
South and Central America
- Market Share: The emerging market is growing in outsourcing demand, impelled by patients' localized needs.
- Key Drivers: The growth of private clinics and specialist centers and the development of public-private partnerships in healthcare.
- Trends: Increased technology transfer agreements with foreign CDMOs to boost local capabilities for complex small-molecule synthesis and development.
Middle East and Africa
- Market Share: Developing market with strong future growth potential due to significant governmental healthcare expenditure.
- Key Drivers: Healthcare infrastructure expansion through national health strategies, and rising demand for complex medical device procedures.
- Trends: Establishment of new biopharma industrial parks and a strategic focus on reducing reliance on imported finished drug products to achieve self-sufficiency.
High Market Density and Innovation Race
Competition is intensifying due to the presence of major vendors such as Lonza, Catalent, Samsung Biologics, Thermo Fisher Scientific, WuXi AppTec, and Recipharm. Established companies and specialized players contribute to the crowded market landscape.
This competitive environment pushes vendors to differentiate through:
- Specialized capabilities in complex modalities like ADCs and Cell & Gene Therapy.
- Global reach and end-to-end service integration (from API to fill/finish).
- Regulatory expertise for global market access.
Opportunities and Strategic Moves
- Partner with technology firms to support the digital transformation of process optimization.
- Incorporate AI/ML for predictive analytics and operational forecasting.
- Lonza Group Ltd.
- Catalent Inc.
- Samsung Biologics
- Thermo Fisher Scientific Inc.
- WuXi AppTec
- Recipharm AB
Disclaimer: The companies listed above are not ranked in any particular order.
Oncology CDMO Market News and Recent Developments- Lonza Delivers Strong Q3 2025 Performance and Confirms Upgraded Full-Year Outlook.: Lonza reported robust Q3 2025 results across its CDMO divisions, including Integrated Biologics, Advanced Synthesis, and Specialized Modalities. The company secured key strategic long-term contracts, notably a major integrated drug substance and drug product supply agreement for bioconjugates and a multi-year commercial deal for small molecules. Lonza's expansion projects are advancing, including the commencement of full commercial operations at its highly potent API plant in Visp and the start of GMP production at its new large-scale mammalian facility, supporting its upgraded 2025 outlook of 20–21% CER sales growth and a 30–31% CORE EBITDA margin.
- Catalent Partners with Siren Biotechnology to Manufacture AAV Gene Therapies for Cancer. : Catalent entered a strategic partnership with Siren Biotechnology to advance adeno-associated viral (AAV) vector-based immuno-gene therapies aimed at oncology applications. Leveraging its expertise in advanced modalities, Catalent is set to provide process development and cGMP manufacturing support at its Baltimore facility. This collaboration reinforces Catalent’s leading position in AAV manufacturing and its dedication to accelerating gene therapy treatments for cancer patients.
The "Oncology CDMO Market Size and Forecast (2025–2031)" report provides a detailed analysis of the market covering below areas:
- Oncology CDMO Market size and forecast at global, regional, and country levels for all the key market segments covered under the scope
- Oncology CDMO Market trends, as well as market dynamics such as drivers, restraints, and key opportunities
- Detailed PEST and SWOT analysis
- Oncology CDMO Market analysis covering key market trends, global and regional framework, major players, regulations, and recent market developments
- Industry landscape and competition analysis covering market concentration, heat map analysis, prominent players, and recent developments in the Oncology CDMO Market
- Detailed company profiles
Have a question?
Mrinal
Mrinal will walk you through a 15-minute call to present the report’s content and answer all queries if you have any.
Speak to Analyst
- Sample PDF showcases the content structure and the nature of the information with qualitative and quantitative analysis.
- Request discounts available for Start-Ups & Universities
- Sample PDF showcases the content structure and the nature of the information with qualitative and quantitative analysis.
- Request discounts available for Start-Ups & Universities
Report Coverage
Revenue forecast, Company Analysis, Industry landscape, Growth factors, and Trends
Segment Covered
This text is related
to segments covered.
Regional Scope
North America, Europe, Asia Pacific, Middle East & Africa, South & Central America
Country Scope
This text is related
to country scope.
Frequently Asked Questions
Oncology CDMOs (Contract Development and Manufacturing Organizations) provide outsourced, end-to-end services for complex cancer drugs, covering preclinical development, formulation, analytical testing, regulatory support, and commercial-scale production, often specializing in highly potent APIs (HPAPIs).
The market is driven by the rising global cancer burden, the increasing adoption of highly complex advanced therapies like Antibody-Drug Conjugates (ADCs) and Cell & Gene Therapies, and pharmaceutical companies' need for regulatory compliance and faster time-to-market.
There is significant demand for CDMOs with specialized capabilities in manufacturing advanced, large-molecule therapies, specifically Monoclonal Antibodies, Antibody-Drug Conjugates (ADCs), and viral vectors for Cell & Gene Therapies.
The market features high competition among key players such as Lonza Group Ltd., Catalent Inc., Samsung Biologics, Thermo Fisher Scientific Inc., WuXi AppTec, and Recipharm AB.
The Asia Pacific (APAC) region is expected to show the fastest growth rate, fueled by rising cancer incidence, expanding clinical trials, government support for the pharmaceutical industry, and the availability of cost-efficient manufacturing.
Yes! We provide a free sample of the report, which includes Report Scope (Table of Contents), report structure, and selected insights to help you assess the value of the full report. Please click on the "Download Sample" button or contact us to receive your copy.
Absolutely - analyst assistance is part of the package. You can connect with our analyst post-purchase to clarify report insights, methodology or discuss how the findings apply to your business needs.
Once your order is successfully placed, you will receive a confirmation email along with your invoice.
• For published reports: You'll receive access to the report within 4-6 working hours via a secured email sent to your email.
• For upcoming reports: Your order will be recorded as a pre-booking. Our team will share the estimated release date and keep you informed of any updates. As soon as the report is published, it will be delivered to your registered email.
We offer customization options to align the report with your specific objectives. Whether you need deeper insights into a particular region, industry segment, competitor analysis, or data cut, our research team can tailor the report accordingly. Please share your requirements with us, and we'll be happy to provide a customized proposal or scope.
The report is available in either PDF format or as an Excel dataset, depending on the license you choose.
The PDF version provides the full analysis and visuals in a ready-to-read format. The Excel dataset includes all underlying data tables for easy manipulation and further analysis.
Please review the license options at checkout or contact us to confirm which formats are included with your purchase.
Our payment process is fully secure and PCI-DSS compliant.
We use trusted and encrypted payment gateways to ensure that all transactions are protected with industry-standard SSL encryption. Your payment details are never stored on our servers and are handled securely by certified third-party processors.
You can make your purchase with confidence, knowing your personal and financial information is safe with us.
Yes, we do offer special pricing for bulk purchases.
If you're interested in purchasing multiple reports, we're happy to provide a customized bundle offer or volume-based discount tailored to your needs. Please contact our sales team with the list of reports you're considering, and we'll share a personalized quote.
Yes, absolutely.
Our team is available to help you make an informed decision. Whether you have questions about the report's scope, methodology, customization options, or which license suits you best, we're here to assist. Please reach out to us at sales@theinsightpartners.com, and one of our representatives will get in touch promptly.
Yes, a billing invoice will be automatically generated and sent to your registered email upon successful completion of your purchase.
If you need the invoice in a specific format or require additional details (such as company name, GST, or VAT information), feel free to contact us, and we'll be happy to assist.
Yes, certainly.
If you encounter any difficulties accessing or receiving your report, our support team is ready to assist you. Simply reach out to us via email or live chat with your order information, and we'll ensure the issue is resolved quickly so you can access your report without interruption.
The Insight Partners performs research in 4 major stages: Data Collection & Secondary Research, Primary Research, Data Analysis and Data Triangulation & Final Review.
- Data Collection and Secondary Research:
As a market research and consulting firm operating from a decade, we have published many reports and advised several clients across the globe. First step for any study will start with an assessment of currently available data and insights from existing reports. Further, historical and current market information is collected from Investor Presentations, Annual Reports, SEC Filings, etc., and other information related to company’s performance and market positioning are gathered from Paid Databases (Factiva, Hoovers, and Reuters) and various other publications available in public domain.
Several associations trade associates, technical forums, institutes, societies and organizations are accessed to gain technical as well as market related insights through their publications such as research papers, blogs and press releases related to the studies are referred to get cues about the market. Further, white papers, journals, magazines, and other news articles published in the last 3 years are scrutinized and analyzed to understand the current market trends.
- Primary Research:
The primarily interview analysis comprise of data obtained from industry participants interview and answers to survey questions gathered by in-house primary team.
For primary research, interviews are conducted with industry experts/CEOs/Marketing Managers/Sales Managers/VPs/Subject Matter Experts from both demand and supply side to get a 360-degree view of the market. The primary team conducts several interviews based on the complexity of the markets to understand the various market trends and dynamics which makes research more credible and precise.
A typical research interview fulfils the following functions:
- Provides first-hand information on the market size, market trends, growth trends, competitive landscape, and outlook
- Validates and strengthens in-house secondary research findings
- Develops the analysis team’s expertise and market understanding
Primary research involves email interactions and telephone interviews for each market, category, segment, and sub-segment across geographies. The participants who typically take part in such a process include, but are not limited to:
- Industry participants: VPs, business development managers, market intelligence managers and national sales managers
- Outside experts: Valuation experts, research analysts and key opinion leaders specializing in the electronics and semiconductor industry.
Below is the breakup of our primary respondents by company, designation, and region:
Once we receive the confirmation from primary research sources or primary respondents, we finalize the base year market estimation and forecast the data as per the macroeconomic and microeconomic factors assessed during data collection.
- Data Analysis:
Once data is validated through both secondary as well as primary respondents, we finalize the market estimations by hypothesis formulation and factor analysis at regional and country level.
- 3.1 Macro-Economic Factor Analysis:
We analyse macroeconomic indicators such the gross domestic product (GDP), increase in the demand for goods and services across industries, technological advancement, regional economic growth, governmental policies, the influence of COVID-19, PEST analysis, and other aspects. This analysis aids in setting benchmarks for various nations/regions and approximating market splits. Additionally, the general trend of the aforementioned components aid in determining the market's development possibilities.
- 3.2 Country Level Data:
Various factors that are especially aligned to the country are taken into account to determine the market size for a certain area and country, including the presence of vendors, such as headquarters and offices, the country's GDP, demand patterns, and industry growth. To comprehend the market dynamics for the nation, a number of growth variables, inhibitors, application areas, and current market trends are researched. The aforementioned elements aid in determining the country's overall market's growth potential.
- 3.3 Company Profile:
The “Table of Contents” is formulated by listing and analyzing more than 25 - 30 companies operating in the market ecosystem across geographies. However, we profile only 10 companies as a standard practice in our syndicate reports. These 10 companies comprise leading, emerging, and regional players. Nonetheless, our analysis is not restricted to the 10 listed companies, we also analyze other companies present in the market to develop a holistic view and understand the prevailing trends. The “Company Profiles” section in the report covers key facts, business description, products & services, financial information, SWOT analysis, and key developments. The financial information presented is extracted from the annual reports and official documents of the publicly listed companies. Upon collecting the information for the sections of respective companies, we verify them via various primary sources and then compile the data in respective company profiles. The company level information helps us in deriving the base number as well as in forecasting the market size.
- 3.4 Developing Base Number:
Aggregation of sales statistics (2020-2022) and macro-economic factor, and other secondary and primary research insights are utilized to arrive at base number and related market shares for 2022. The data gaps are identified in this step and relevant market data is analyzed, collected from paid primary interviews or databases. On finalizing the base year market size, forecasts are developed on the basis of macro-economic, industry and market growth factors and company level analysis.
- Data Triangulation and Final Review:
The market findings and base year market size calculations are validated from supply as well as demand side. Demand side validations are based on macro-economic factor analysis and benchmarks for respective regions and countries. In case of supply side validations, revenues of major companies are estimated (in case not available) based on industry benchmark, approximate number of employees, product portfolio, and primary interviews revenues are gathered. Further revenue from target product/service segment is assessed to avoid overshooting of market statistics. In case of heavy deviations between supply and demand side values, all thes steps are repeated to achieve synchronization.
We follow an iterative model, wherein we share our research findings with Subject Matter Experts (SME’s) and Key Opinion Leaders (KOLs) until consensus view of the market is not formulated – this model negates any drastic deviation in the opinions of experts. Only validated and universally acceptable research findings are quoted in our reports.
We have important check points that we use to validate our research findings – which we call – data triangulation, where we validate the information, we generate from secondary sources with primary interviews and then we re-validate with our internal data bases and Subject matter experts. This comprehensive model enables us to deliver high quality, reliable data in shortest possible time.
Get Free Sample For